While the uses of cyclodextrin as active ingredients is emerging both by the number of target diseases, companies developing them and types of CDs used, their efficient delivery remains a challenge.
The nanobubbles presented here could incorporate the CDs, accumulate in the atherosclerotic lesions, the release of CD and the reduce the total plaque area in the entire aorta and eventually reduce cholesterol level in mice plasma.
Cyclodextrin-loaded nanobubbles reduce cholesterol and atherosclerosis in vivo | European Heart Journal | Oxford Academic (oup.com)
